Current Treatments for HCV
|
|
- Ralf Preston
- 6 years ago
- Views:
Transcription
1 Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen, Merck, Novartis, Vertex Grant/Research Support: Abbott, Achillion, Anadys, Beckman-Colter, BMS, Boehringer-Ingelheim, Genentech, Gilead, Globeimmune, Idenix, Merck, Novartis Speakers Bureau: Genentech, Gilead, GSK, Merck, Vertex CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Copyright 213 American College of Gastroenterology 1
2 POTENTIAL CONFLICTS OF INTEREST Abott: DSMB, G Anadys: DSMB, G Bayer: S Bristol-Myers-Squibb: A,G,S Conatus: A,G Exalenz: A Genentech/Roche: A,C,G,S Gilead: A,G,S Globeimmune: A,G Idenix: G Inhibitex: A,G Intercept: A,G Merck/Schering-Plough: A,G,S Novartis: A,G Pfizer: A Romark:C Salix: A,S Vertex: A,S Human Genome Sciences: C Zymogenetics: A,G A=Advisor, C=Consultant, G=Grants, S=Speaker CURRENT TREATMENT FOR HCV GENOTYPE 1 Peginterferon, ribavirin and an HCV protease inhibitor Telaprevir Boceprevir Protease inhibitors: Genotype specific Not generally effective against other HCV genotypes Must be utilized with Peginterferon and ribavirin Both protease inhibitors act at the same site Virologic failure cannot be overcome by the other agent Both protease inhibitors yield similar results Copyright 213 American College of Gastroenterology 2
3 TREATMENT NAÏVE TELAPREVIR Naïve Caucasian AA TPV Placebo IM Jacobson et al. N Eng J Med 211; 364: TREATMENT NAÏVE BOCEPREVIR Naïve Caucasian AA BOC Placebo F Poordad et al. N Engl J Med 211; 364: Copyright 213 American College of Gastroenterology 3
4 TREATMENT NAÏVE TELAPREVIR Mild BF/Cx <8K >8K 1A 1B Fibrosis HCV RNA Genotype TPV Placebo IM Jacobson et al. N Eng J Med 211; 364: TREATMENT NAÏVE TELAPREVIR Mild BF/Cx <8K >8K 1A 1B Fibrosis HCV RNA Genotype TPV Placebo IM Jacobson et al. N Eng J Med 211; 364: Copyright 213 American College of Gastroenterology 4
5 TREATMENT NAÏVE TELAPREVIR Mild BF/Cx <8K >8K 1A 1B Fibrosis HCV RNA Genotype TPV Placebo IM Jacobson et al. N Eng J Med 211; 364: TREATMENT OF CHRONIC HCV DIFFERENT PARADIGMS TELAPREVIR Start Telaprevir with Peginterferon and Ribavirin Continue with Peginterferon and Ribavirin Provide maximal viral suppression with triple therapy up front then stop the anti-viral agent and eradicate HCV with peginterferon and ribavirin BOCEPREVIR Start Peginterferon and Ribavirin as Lead-In Add Boceprevir to Peginterferon and Ribavirin Continue with Peginterferon and Ribavirin Suppress viral species that may be resistant to the anti-viral agent up front then eradicate HCV with triple therapy Copyright 213 American College of Gastroenterology 5
6 Log HCV RNA (IU/ml) EXTENDED RVR RESPONSE GUIDED THERAPY 7 Developed from observations Telaprevir Boceprevir WEEKS made from peginterferon/ribavirin Applied to the triple therapy paradigms Patients who achieve RVR Treated for a shorter duration Achieve maximum SVR Patients with delayed virologic response Become HCV RNA negative after week 4 Require 48 weeks of treatment to reduce relapse Have lower SVR rates TREATMENT NAÏVE - TELAPREVIR RAPID VIROLOGIC RESPONSE Patients (%) TPV 7 Placebo RVR SVR Log HCV RNA (IU/ml) PEG-RBV TPV WEEKS IM Jacobson et al. N Eng J Med 211; 364: Copyright 213 American College of Gastroenterology 6
7 TREATMENT NAÏVE - BOCEPREVIR RAPID VIROLOGIC RESPONSE Patients (%) BOC 7 Placebo RVR SVR Log HCV RNA (IU/ml) PEG-RBV BOC WEEKS IM Jacobson et al. N Eng J Med 211; 364: FDA RECOMMENDED ALGORITHM TELAPREVIR TREATMENT NAIVE TPV+ If ervr: If NO ervr: Measure HCV RNA HCV RNA Hard Stop Rules <1 <1 UD Copyright 213 American College of Gastroenterology 7
8 FDA RECOMMENDED ALGORITHM BOCEPREVIR TREATMENT NAIVE If ervr: BOC+ If NO ervr: BOC+ PEG + RBV Measure HCV RNA HCV RNA Hard Stop Rules <1 UD TREATMENT OF CHRONIC HCV SVR AND TIME TO RESPOND 1 % of Patients Boceprevir Telaprevir RVR Delayed Response TIME OF VIROLOGIC RESPONSE ML Shiffman and R Estaban Liver Intl 212; 32 (suppl 1):54-6. Copyright 213 American College of Gastroenterology 8
9 TELAPREVIR PHASE 3 ADVANCE SUDY NAÏVE: 8 vs 12 WEEKS Telaprevir PEGIFN-2a Ribavirin Telaprevir PEGIFN-2a Ribavirin If ervr: PEGINF + Ribavirin If NO ervr: PEGINF + Ribavirin Weeks of TPV Overall SVR % 89% 5% 54% 69% 75% PEGINF-2a + Ribavirin 44% 4 8 IM Jacobson et al. N Eng J Med 211; 364: Weeks RETREATMENT OF CHRONIC HCV VIROLOGIC RESPONSE PATTERNS Log HCV RNA (IU/ml) Peginterferon/Ribavirin 2-log decline Limit of detection WEEKS A Sethi and ML Shifman Clin Liver Dis 25; 9: Copyright 213 American College of Gastroenterology 9
10 RETREAT PEGINF/RIBAVIRIN FAILURES TELAPREVIR Relapse Partial Null PRIOR TREATMENT RESPONSE TPV Placebo S Zeuzem et al. N Eng J Med 211; 364: RETREAT PEGINF/RIBAVIRIN FAILURES BOCEPREVIR Relapse Partial Unresponsive PRIOR TREATMENT During Lead-In B Bacon et al. N Engl J Med 211; 364: BOC Placebo Copyright 213 American College of Gastroenterology 1
11 FDA RECOMMENDED ALGORITHM TELAPREVIR Treatment naïve and Prior Relapse TPV+ If ervr: If NO ervr: Measure HCV RNA HCV RNA Hard Stop Rules <1 <1 UD FDA RECOMMENDED ALGORITHM TELAPREVIR Treatment naïve and Prior Relapse TPV+ If ervr: If NO ervr: Prior Non-Response and Cirrhosis TPV HCV RNA Hard Stop Rules <1 <1 UD Copyright 213 American College of Gastroenterology 11
12 FDA RECOMMENDED ALGORITHM BOCEPREVIR Prior Relapse Partial Response If ervr: BOC+ If NO ervr: BOC+ PEG + RBV Measure HCV RNA HCV RNA Hard Stop Rules <1 UD FDA RECOMMENDED ALGORITHM BOCEPREVIR Prior Relapse Partial Response If ervr: BOC+ If NO ervr: BOC+ PEG + RBV Prior Null Response INF Insensitive Cirrhosis BOC HCV RNA Hard Stop Rules <1 UD Copyright 213 American College of Gastroenterology 12
13 TREATMENT OF HCV INTERFERON RESPONSIVENESS Even with a protease inhibitor achieving SVR is still dependent upon the ability to respond to interferon Can be assessed by prior treatment response Relapse highly responsive Null response poorly responsive Interferon responsiveness is genetically mediated IL28B genotype CC highly responsive IL28B genotype TT poorly responsive Can be assessed by a lead-in response INTERFERON RESPNSIVENESS PRIOR TREATMENT RESPONSE TPV BOC Relapse Partial Null PRIOR TREATMENT RESPONSE S Zeuzem et al. N Eng J Med 211; 364: B Bacon et al. N Engl J Med 211; 364: Copyright 213 American College of Gastroenterology 13
14 INTERFERON RESPONSIVENESS IL28B GENOTYPE TPV BOC PEGINF/R CC CT TT IL28B GENOTYPE IM Jacobson et al. EASL 211 F Poordad et al. EASL 211 INTERFERON RESPONSIVENESS RESPONSE TO LEAD-IN 1 8 Yes No Naïve Retreatment Log HCV RNA (IU/ml) PEG-RBV BOC >1 log decline in HCV RNA WEEKS F Poordad et al. N Engl J Med 211; 364: B Bacon et al. N Engl J Med 211; 364: Copyright 213 American College of Gastroenterology 14
15 RESISTANCE TO PROTEASE INHIBITORS QUASISPECIES Single or multiple changes to the genetic sequence of HCV New quasispecies form all the time A-T-A-T-A-T-A-T-A-T-A-T-A-T- A-T-A-T-C-T-C-T-A-T-A-T-A-T- A-T-A-T-G-T-G-T-A-T-A-T-A-T- A-T-G-T-A-T-A-T-T-T-A-T-A-T- May lead to resistance against anti-viral agents Every patient infected with 1s of different quasispecies CHRONIC HCV POOL OF VIRAL SPECIES.A-T-A-G-C-T..A-T-A-G-C-T..A-T-A-G-C-T..A-T-A-G-C-T..A-T-C*-G-C-T..A-T-A-G-C-T..A-A*-A-G-C-T..A-T-C*-G-C-T..A-T-A-G-C-T..A-T-A-G-C-T..A-T-A-G-C-T..A-T-A-G-C-T. Copyright 213 American College of Gastroenterology 15
16 CHRONIC HCV IMPACT OF VIRAL MUTATIONS Wild type viral protein Anti-viral agent enters the binding site Viral protein inhibited Sensitive mutant viral protein Anti-viral agent still able to enter binding site Viral protein inhibited Resistant mutant viral protein Anti-viral agent unable to enter binding site Viral protein not inhibited HEPATITIS C VIRUS A POOL OF VIRUS Sensitive mutant Wild type Sensitive mutant Sensitive mutant Resistant mutants Copyright 213 American College of Gastroenterology 16
17 TREATMENT OF CHRONIC HCV EMERGENCE OF RESISTANCE rus (IU/ml) Vi "Wild Type" Sensitive mutant Resistant mutant ML Shiffman Clin Liver Dis 211; 15: Time MEASURING HCV RNA STOP RULES Log HCV RNA (IU/ml ) Telaprevir TREATMENT WEEK Log HCV RNA (IU/ml ) Boceprevir TREATMENT WEEK Copyright 213 American College of Gastroenterology 17
18 GENOTYPES 2 AND 3 IMPACT OF NOT ACHIEVING RVR Patients without RVR Yes RVR No Weeks of Treatment ML Shiffman et al. N Eng J Med 27; 357: B Willems, et al. EASL 27. HCV GENOTYPES 2 AND 3 RESPONSE GUIDED THERAPY RCT comparing 24 vs 48 Weeks of treatment in patients without RVR STOP Measure HCV RNA RVR Randomize if HCV RNA (-) ML Shiffman et al. J Hepatology 213; (submitted) Wks of Treatment Copyright 213 American College of Gastroenterology 18
19 CURRENT TREATMENT FOR HCV SUMMARY Either telaprevir or boceprevir combined with peginterferon and ribavirin is the current standard of care for patients with HCV genotype 1 Superior results in all patient groups compared to peginterferon and ribavirin Paradigms for the 2 drugs are different but yield similar results About 6% of patients will achieve a sustained virologic response and can be treated for only weeks The ability to be cured of HCV is dependent upon interferon responsiveness Must adhere to strict stopping rules to avoid the emergence of resistant mutations Response guided therapy should be utilized for patients with genotypes 2, 3 and 4 Copyright 213 American College of Gastroenterology 19
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationCurrent Standards in the Treatment of Chronic Hepatitis C
REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationRBV DR (n=249) EPO (n=251)
Eric Lawitz, Stefan Zeuzem, Lisa Nyberg, David Nelson, Lorenzo Rossaro, Luis Balart, K. Rajender Reddy, Timothy Morgan, Weiping Deng, Ken Koury, Katia Alves, Frank Dutko, Janice Wahl, Lisa D. Pedicone,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationTreatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin
ORIGINAL CONTRIBUTIONS nature publishing group 1179 see related editorial on page x Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon
More informationOptimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
Journal of Viral Hepatitis, 2012, 19, 766 774 doi:1111/j.1365-2893.2012.01624.x Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationIMPACT OF HCV THERAPY ON METABOLISM AND PUBLIC HEALTH
IMPACT OF HCV THERAPY ON METABOLISM AND PUBLIC HEALTH Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need DISCLOSURES CONFLICTS OF INTEREST
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationHepatitis C virus (HCV) infects more than
Retreatment with Telaprevir Combination Therapy in Hepatitis C Patients with Well-Characterized Prior Treatment Response Andrew J. Muir, 1 Fred F. Poordad, 2 John G. McHutchison, 1 Mitchell L. Shiffman,
More informationComparing the Different Guidelines
Comparing the Different Guidelines Fred Poordad, MD Professor of Medicine University of Texas Health Science Center VP, Academic and Clinical Affairs Texas Liver Institute San Antonio, TX Disclosures Grant/Research
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationOnset of the AIDS pandemic in the early
REVIEWS Treatment Failure and Resistance with Direct-Acting Antiviral Drugs Against Hepatitis C Virus Jean-Michel Pawlotsky 1,2 Current treatment of chronic hepatitis C virus (HCV) infection is based on
More informationAntiviral Therapy 2016; 21: (doi: /IMP3062)
Antiviral Therapy 2016; 21:679 687 (doi: 10.3851/IMP3062) Original article Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase
More informationBOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationChronic infection with hepatitis C virus (HCV)
VIRAL HEPATITIS Concordance of Sustained Virological Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir- Containing Regimens for Hepatitis C Virus Eric M. Yoshida, 1 Mark S. Sulkowski, 2 Edward
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationABSTRACT. n engl j med 370;20 nejm.org may 15,
The new england journal of medicine established in 1812 may 15, 2014 vol. 370 no. 20 Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Kris V. Kowdley, M.D., Stuart C. Gordon,
More informationAnemia is a well-established adverse event with both
GASTROENTEROLOGY 2013;145:1035 1044 Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection A Randomized Trial
More informationArticles. Funding Gilead Sciences.
in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Eric Lawitz,
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationMany promising small molecule inhibitors directed
GASTROENTEROLOGY 2012;142:1351 1355 Will Interferon-Free Regimens Prevail? Christoph Welsch Stefan Zeuzem Department of Internal Medicine I, J. W. Goethe University Hospital, Frankfurt/Main, Germany Many
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationTREATMENT OF HCV DECOMPENSATED CIRRHOSIS
TREATMENT OF HCV DECOMPENSATED CIRRHOSIS Mitchell L Shiffman, MD Director Richmond and Newport News, VA Good Help to Those in Need ML SHIFFMAN DISCLOSURE OF CONFLICTS Company Roles Company Roles Abbvie
More informationThe leading cause of cirrhosis and hepatocellular
Safety and Efficacy of Ledipasvir-Sofosbuvir in Black Patients With Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data Julius M. Wilder, 1 Lennox J. Jeffers, 2 Natarajan Ravendhran,
More informationCombination therapy with peginterferon alfa/
Refinement of Stopping Rules During Treatment of Hepatitis C Genotype 1 Infection With Boceprevir and Peginterferon/Ribavirin Ira M. Jacobson, 1 Patrick Marcellin, 2 Stefan Zeuzem, 3 Mark S. Sulkowski,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationHepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012
Reports From the Liver Meeting 212 Project ID: 521 Target Audience This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, physician assistants, and nurse practitioners
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More information